Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. The aim of the study was to document postheparin plasma lipoprotein lipase (LPL) and hepatic lipase activities and relate these to serum lipid, lipoprotein and apolipoprotein concentrations in 85 patients with kidney function ranging from normal to dialysis dependency. Strict selection criteria were applied in order to exclude conditions other than renal failure which may influence lipid metabolism. Stress was laid on minimizing proteinuria and inflammatory activity. The changes in the lipoprotein pattern were numerically strikingly modest compared to those previously reported. This probably reflected the intenti...
The institution of renal replacement therapy has sustained the lives of many patients with end-stage...
Chronic kidney disease (CKD) is associated with dyslipidemia, characterized by increased levels of t...
This study compared the molecular lipidomic profi le of LDL in patients with nondiabetic advanced re...
Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertrig...
Increased lipase inhibition in uremia: Identification of pre-β-HDL as a major inhibitor in normal an...
Ongoing clinical trials of lipid reduction therapy in patients with renal diseaseBackgroundLipid abn...
Plasma samples were obtained from seven hypertriglyceridemic (\u3e150 mg/dl) chronic renal failure p...
Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein ...
Mortality from cardiovascular disease in patients on chronic hemodialysis (HD) is 10 to 20 times gre...
Impaired metabolism of high density lipoprotein in uremic patients. We measured lipoproteins, apolip...
Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. The relati...
Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiencyBackgroundIncrea...
Abstract Background Lipoprotein lipase (LPL) has a central role in the catabolism of triglyceride-ri...
Apolipoprotein Cs (apoC-1, apoC-II, and apoC-III) are lipoprotein components that have regulatory ef...
Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal diseaseRenal disease is...
The institution of renal replacement therapy has sustained the lives of many patients with end-stage...
Chronic kidney disease (CKD) is associated with dyslipidemia, characterized by increased levels of t...
This study compared the molecular lipidomic profi le of LDL in patients with nondiabetic advanced re...
Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertrig...
Increased lipase inhibition in uremia: Identification of pre-β-HDL as a major inhibitor in normal an...
Ongoing clinical trials of lipid reduction therapy in patients with renal diseaseBackgroundLipid abn...
Plasma samples were obtained from seven hypertriglyceridemic (\u3e150 mg/dl) chronic renal failure p...
Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein ...
Mortality from cardiovascular disease in patients on chronic hemodialysis (HD) is 10 to 20 times gre...
Impaired metabolism of high density lipoprotein in uremic patients. We measured lipoproteins, apolip...
Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. The relati...
Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiencyBackgroundIncrea...
Abstract Background Lipoprotein lipase (LPL) has a central role in the catabolism of triglyceride-ri...
Apolipoprotein Cs (apoC-1, apoC-II, and apoC-III) are lipoprotein components that have regulatory ef...
Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal diseaseRenal disease is...
The institution of renal replacement therapy has sustained the lives of many patients with end-stage...
Chronic kidney disease (CKD) is associated with dyslipidemia, characterized by increased levels of t...
This study compared the molecular lipidomic profi le of LDL in patients with nondiabetic advanced re...